Kiniksa Pharmaceuticals
(NASDAQ:KNSA)
$19.99
0[0.00%]
Last update: 4:00PM Get Real Time Here
Consensus Rating1
Buy
Highest Price Target1
$34.00
Lowest Price Target1
$20.00
Consensus Price Target1
$27.75

Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA), Analyst Ratings, Price Targets, Predictions

Kiniksa Pharmaceuticals Ltd has a consensus price target of $27.75, established from looking at the 4 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Goldman Sachs, and JP Morgan on January 2, 2024, July 26, 2023, and March 9, 2023. With an average price target of $25.67 between Wedbush, Goldman Sachs, and JP Morgan, there's an implied 31.22% upside for Kiniksa Pharmaceuticals Ltd from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Jan
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wedbush
Goldman Sachs
JP Morgan
B of A Securities

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Kiniksa Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
01/02/2024KNSABuy Now
Kiniksa Pharmaceuticals
$19.5627.81%Wedbush
David Nierengarten
$23 → $25MaintainsOutperformGet Alert
07/26/2023KNSABuy Now
Kiniksa Pharmaceuticals
$19.5663.6%Goldman Sachs
Paul Choi
$22 → $32MaintainsBuyGet Alert
03/09/2023KNSABuy Now
Kiniksa Pharmaceuticals
$19.562.25%JP Morgan
Anupam Rama
$19 → $20MaintainsOverweightGet Alert
12/29/2021KNSABuy Now
Kiniksa Pharmaceuticals
$19.5673.82%B of A Securities
Geoff Meacham
$37 → $34MaintainsBuyGet Alert

FAQ

Q

What is the target price for Kiniksa Pharmaceuticals (KNSA)?

A

The latest price target for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was reported by Wedbush on January 2, 2024. The analyst firm set a price target for $25.00 expecting KNSA to rise to within 12 months (a possible 25.06% upside). 2 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?

A

The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was provided by Wedbush, and Kiniksa Pharmaceuticals maintained their outperform rating.

Q

When was the last upgrade for Kiniksa Pharmaceuticals (KNSA)?

A

There is no last upgrade for Kiniksa Pharmaceuticals.

Q

When was the last downgrade for Kiniksa Pharmaceuticals (KNSA)?

A

There is no last downgrade for Kiniksa Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on January 2, 2024 so you should expect the next rating to be made available sometime around January 2, 2025.

Q

Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?

A

While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $23.00 to $25.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $19.99, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch